Motus GI Holdings Inc (NASDAQ:MOTS) has been assigned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $10.63.
MOTS has been the topic of a number of recent research reports. ValuEngine raised shares of Motus GI from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. LADENBURG THALM/SH SH initiated coverage on shares of Motus GI in a research report on Thursday, August 30th. They issued a “buy” rating and a $14.50 target price on the stock. Oppenheimer reaffirmed a “buy” rating on shares of Motus GI in a research report on Tuesday, September 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $8.00 target price on shares of Motus GI in a research report on Tuesday, August 14th. Finally, Dougherty & Co initiated coverage on shares of Motus GI in a research report on Tuesday, August 28th. They issued a “buy” rating and a $8.00 target price on the stock.
Several large investors have recently added to or reduced their stakes in the company. IPG Investment Advisors LLC purchased a new stake in shares of Motus GI in the 2nd quarter worth about $106,000. Quantitative Systematic Strategies LLC purchased a new stake in Motus GI during the 2nd quarter valued at about $113,000. Finally, Highbridge Capital Management LLC purchased a new stake in Motus GI during the 1st quarter valued at about $896,000. 21.61% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:MOTS opened at $4.44 on Wednesday. The stock has a market capitalization of $68.54 million and a PE ratio of -3.47. Motus GI has a 1-year low of $3.75 and a 1-year high of $10.66.
Motus GI (NASDAQ:MOTS) last released its earnings results on Tuesday, August 14th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.01). The firm had revenue of $0.03 million for the quarter. As a group, research analysts anticipate that Motus GI will post -1.01 earnings per share for the current fiscal year.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
See Also: The Discount Rate – What You Need to Know
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.